Population trends in aspirin use for cardiovascular disease prevention 1980-2009: The minnesota heart survey

Journal of the American Heart Association

Volumn 4, Issue 12, 2015, Pages

  Luepker, Russell V ^a,b   Steffen, Lyn M ^a   Duval, Sue ^b   Zantek, Nicole D ^b   Zhou, Xia ^a   Hirsch, Alan T ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Aspirin; Epidemiology; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; THROMBOXANE B2; ANTITHROMBOCYTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SELF CARE; SELF REPORT; SEX DIFFERENCE; TREND STUDY; UNITED STATES; URBAN POPULATION; AGE; CARDIOVASCULAR DISEASES; MIDDLE AGED; MINNESOTA; QUESTIONNAIRE;

ADULT; AGE FACTORS; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MINNESOTA; PLATELET AGGREGATION INHIBITORS; SEX FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84991521223     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002320     Document Type: Article

References (37)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 Update: a report from the American Heart Association. Circulation. 2013;127: e6-e245.
2. Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010;38:600-609.
3. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
5. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
6. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-313.
7. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009;150:396-404.
8. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research, and the American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2015;132:691-718.
9. Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, Mega JL, Menon V, Page RL II, Newby LK; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Functional Genomics and Translational Biology, Council on the Kidney in Cardiovascular Disease, and Council on Quality of Care and Outcomes Research. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131:1123-1149.
10. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, Lopez-Jimenez F, McNallan SM, Patel M, Roger VL, Sellke FW, Sica DA, Zimmerman L; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131:927-964.
11. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45:3754-3832.
12. Healthy People 2020 objectives. Available at: http://www.healthypeople.gov/2020/topicsobjectives2020/default. Accessed November 7, 2013.
13. Frieden TR, Berwick DM. The "Million Hearts" initiative-preventing heart attacks and strokes. N Engl J Med. 2011;365:e27.
14. Kim C, Beckles GL. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med. 2004;27:1-7.
15. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007;32:403-407.
16. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
17. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30:74-77.
18. Maddox TM, Ho PM, Roe M, Dai D, Tsai TT, Rumsfeld JS. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catherization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. Circ Cardiovasc Qual Outcomes. 2010;3:632-641.
19. Luepker RV, Jacobs DR Jr, Gillum RF, Folsom AR, Prineas RJ, Blackburn H. Population risk of cardiovascular disease: the Minnesota Heart Survey. J Chronic Dis. 1985;38:671-682.
20. Luepker RV, Jacobs DR Jr, Folsom AR, Gillum RF, Frantz ID Jr, Gomez O, Blackburn H. Cardiovascular risk factor change-1973-74 to 1980-82: the Minnesota Heart Survey. J Clin Epidemiol. 1988;41:825-833.
21. Luepker RV, Arnett DK, Jacobs DR Jr, Duval SJ, Folsom AR, Armstrong C, Blackburn H. Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med. 2006;119:42-49.
22. Feldman M, Cryer B, Rushin K, Betancourt J. A comparison of every-third-day versus daily low-dose aspirin therapy on serum thromboxane concentrations in healthy men and women. Clin Appl Thromb Hemost. 2001;7:53-57.
23. Zantek ND, Luepker RV, Duval S, Miller K, Oldenburg N, Hirsch AT. Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement. Clin Appl Thromb Hemost. 2014;20:385-392.
24. Miner J, Hoffhines A. The discovery of aspirin's antithrombotic effects. Tex Heart Inst J. 2007;34:179-186.
25. Craven LL. Acetylsalicylic acid, possible preventive or coronary thrombosis. Ann West Med Surg. 1950;4:95-99.
26. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621-629.
27. Jacoba P, Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117:2875-2883.
28. Shahar E, Folsom AR, Romm FJ, Bisgard KM, Metcalf PA, Crum L, McGovern PG, Hutchinson RG, Heiss G; for the ARIC Study Investigators. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1996;131:915-922.
29. Miedema MD, Cohn JN, Garberich RF, Knickelbine T, Graham KJ, Henry TD. Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. Am Heart J. 2012;164:259-267.
30. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Ngianga-Bakwin K, Grove A, Gurung B, Morrow S, Stranges S, Clarke A. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One. 2013;8: e81970. doi: 10.1371/journal.pone.0081970.
31. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-2141.
32. Williams CD, Chan AT, Elman MR, Kristensen AH, Miser F, Pignone MP, Stafford RS, McGregor JC. Aspirin use among adults in the U.S.: results of a national survey. Am J Prev Med. 2015;48:501-508.
33. Fang J, George MG, Gindi RM, Hong Y, Yang Q, Ayala C, Ward BW, Loustalot F. Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). Am J Cardiol. 2015;115:895-900.
34. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
35. Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Curr Opin Cardiol. 2012;27:499-507.
36. Zhao Y, Encinosa W. Hospitalizations for gastrointestinal bleeding in 1998 and 2006 HCUP Statistical Brief #65. Rockville, MD: Agency for Healthcare Research and Quality; December 2008.
37. Lakshminarayan K, Anderson DC, Zhou X, Barber CA, Steffen LM, Luepker RV. Trends in stroke subtypes: the Minnesota stroke survey. Stroke. 2005;36:505.